FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

| OMB APP | ROVAL |
|--------------------|-----------|
| OMB Number: | 3235-0287 |
| Estimated average | burden |
| hours per response | 0.5 |

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(n). See Instruction 1

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| 1(0). 0 | ee mstruction i | ·. | | | | | | | | | | | | | | | | | |
|--|--|---------|--------------|--|--|--|---|-------------------------|------------------|--------------------|---|---|---|-------------------------------|-----------------------|---|--|-------------------------|---|
| Name and Address of Reporting Person* Carr Patricia | | | | 2. Issuer Name and Ticker or Trading Symbol Jazz Pharmaceuticals plc [JAZZ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) | | | | | | | | | | | | | | | |
| Call Pa | <u>micia</u> | | | | | | | | | | . 1 | | | | Dire | ctor | | 10% Ov | vner |
| , | | | | | | | | | | | | | | 4 | ✓ Office below | er (give title | | Other (s | specify |
| (Last) | (Fi | rst) (M | /liddle) | | | 3. Date of Earliest Transaction (Month/Day/Year) | | | | | | | | | , | oounti | , | or | |
| 5TH FL, WATERLOO EXCHANGE | | | | 01/1 | 7/202 | 25 | | | | | | | | SVP, Chief Accounting Officer | | | | | |
| WATER | LOO RD | | | | 1 | | | | | | | | | | | | | | |
| WATERLOOKD | | | | 4. If Amendment, Date of Original Filed (Month/Day/Year) | | | | | | | 6. | 6. Individual or Joint/Group Filing (Check Applicable | | | | | | | |
| (Street) | | | | | | | , | | | | (| , | ., | Lir | | | | , (| ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,, |
| DUBLIN | 14 L2 | | | | 1 | | | | | | | | | | ▼ Forr | n filed by On | e Repo | orting Perso | on |
| DODLIN | T L2 | | | | 1 | | | | | | | | | | | n filed by Mo | re than | One Repo | orting |
| (O:t) | (0) | -4-> /- | 7: \ | | 1 | | | | | | | | | | Pers | ion | | | |
| (City) | (51 | ate) (Z | <u>Z</u> ip) | | | | | | | | | | | | | | | | |
| | | Table | I - Non | -Deriva | tive S | Secu | rities | Acq | uired, | Dis | posed of | , or l | Ben | eficia | ally Ow | ned | | | |
| 1. Title of Security (Instr. 3) 2. Transac Date Office of the office of | | | | | ction 2A. Deemed Execution Date, if any (Month/Day/Year) | | 3. 4. Securities Acquired (A Disposed Of (D) (Instr. 3, Code (Instr. 5) | | | (A) or . 3, 4 a | A) or 5. Amount o Securities Beneficially | | Form: | Direct | t of Indirect | | | | |
| (worth) | | | | | | | | | | | | | | Owne | d Following | (I) (Ins | str. 4) | Ownership (Instr. 4) | |
| | | | | | | | | Code | v | Amount | (A (D |) or) | Price | Trans | action(s) 3 and 4) | | | (11150.4) | |
| Ordinary Shares 01/17/2 | | | | | /2025 | | | A ⁽¹⁾ | | 1,641 | | A \$0.0 | | 0 | 8,237 | | D | | |
| Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned | | | | | | | | | | | | | | | | | | | |
| | | | | e.g., pu | ıts, ca | alls, | warra | ants, | optior | ıs, c | onvertib | le se | cur | ities |) | | | | |
| 1. Title of Derivative Security (Instr. 3) | Derivative Conversion Date Execution Date, or Exercise (Month/Day/Year) if any | | n Date, | Transaction Code (Instr. 8) | | of Deriv | vative irities ired r osed) | Expiration Date | | te Amount of | | f g | 8. Price of Derivative Security (Instr. 5) | | | IO. Dwnership Form: Direct (D) or Indirect I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | | |
| | | | | | Code | v | (A) | | Date Exercisa | able | Expiration Date | Title | or Nur of | ount nber ires | | | | | |

Explanation of Responses:

1. Represents ordinary shares of Jazz Pharamceuticals that will be delivered pursuant to the terms of performance share awards made to the reporting person on March 3, 2022. The performance-based vesting requirements applicable to such awards were satisfied on January 17, 2025, which represents the date on which the level of performance attained was certified.

By: /s/Adam Guttmann, as attorney in fact For: Patricia

Carr

** Signature of Reporting Person Date

01/22/2025

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.